semaglutide / tirzepatide vs Semaglutide: 2026 Clinical Comparison Weight loss: Semaglutide or tirzepatide,

Lancet 2009;373(9681):21252135

Most patients remain on weight loss drugs for a minimum of 6 to 12 months

Key Takeaways Semaglutide belongs to the GLP-1 receptor agonist category that aims to mimic the naturally occurring GLP-1 hormone in the body to address type 2 diabetes and chronic weight management

Factors such as diet, exercise, individual response to the medication, and overall health play crucial roles

In patients with diabetes and a history of peripheral vascular events, GLP-1 therapies were associated with reduced risk of amputation, major adverse cardiovascular events, cardiovascular death, all-cause mortality, and progression to dialysis compared with other glucose-lowering medications (Hsiao et al., 2026)